Melanoma incidence is rising rapidly worldwide among white skinned populations. Earlier diagnosis is the principal factor that can improve prognosis. Defining high-risk populations using risk prediction models may help targeted screening and early detection approaches. In this systematic review we searched Medline, EMBASE and the Cochrane Library for primary research studies reporting or validating models to predict risk of developing cutaneous melanoma. 4141 papers were identified from the literature search and six through citation searching. 25 risk models were included. Between them, the models considered 144 possible risk factors, including 18 measures of number of naevi and 26 of sun/UV exposure. Those most frequently included in final risk models were number of naevi, presence of freckles, history of sunburn, hair colour and skin colour. Despite the different factors included and different cut-offs for sensitivity and specificity, almost all models yielded sensitivities and specificities that fit along a summary ROC with AUROC of 0.755, suggesting most models had similar discrimination. Only 2 models have been validated in separate populations and both also showed good discrimination with AUROC values of 0.79 (0.70-0.86) and 0.70 (0.64-0.77). Further research should focus on validating existing models rather than developing new ones.
INTRODUCTION
Melanoma is one of the fastest growing cancers worldwide: age adjusted incidence rates have been increasing in most of the fair-skinned populations in recent decades; and 160000 new cases are diagnosed annually worldwide (1) (2) (3) (4) (5) . As earlier diagnosis is the principal factor that can improve the prognosis of patients with melanoma (6), there is considerable interest in the development of screening programmes. The SCREEN project in northern Germany suggested that population screening may have a substantial impact on melanoma incidence and 5 year mortality (7, 8) leading to the implementation of a national statutory skin cancer early detection program in Germany in 2008. However, such mass screening is not currently recommended by the US Preventive Services Task Force (9) or in other countries. Modelling studies suggest that selective, targeted screening might be a more cost-effective strategy (10, 11). Such a stratified approach is currently recommended by the Royal Australian College of General Practitioners. Australian primary care physicians are advised to perform skin examinations every 3-12 months in people with multiple atypical or dysplastic naevi and a history of melanoma or a first-degree relative with melanoma (12).
This approach is also being considered by the Department of Health in the United Kingdom.
The aims of such targeted screening programs are to identify people at higher risk of melanoma and to offer them preventive advice about sun protection and skin awareness and early consultation or surveillance (13) (14) (15) . The identification of people at higher risk may be improved by the use of risk prediction models. Several risk models have been developed but their strengths, weaknesses and relative performance are uncertain. We report a systematic review and comparison of risk prediction models for melanoma. 
MATERIALS AND METHODS

Search strategy
An electronic literature search of Medline, EMBASE and the Cochrane Library up to August 2013 was performed using a combination of subject headings and free text incorporating 'melanoma', 'risk/risk factor/risk assessment/chance' and 'prediction/model/score' (see Supplementary File 1 for complete search strategy). We then manually screened the reference lists of all included papers.
Study selection
Studies were included if they fulfilled all of the following criteria: (i) are published as a primary research paper in a peer-reviewed journal; (ii) identify risk factors for developing melanoma at the level of the individual; (iii) provide a measure of relative or absolute risk using a combination of risk factors that allows identification of people at higher risk of melanoma; (iv) use a statistical method to develop the final risk model; and (iv) are applicable to the general population. As the focus of the review is to summarise the risk prediction models for incident melanoma, studies developing models for the risk of recurrence and prognostic models were excluded. Studies including only highly selected groups, for example immunosuppressed patients or those with a previous history of cancer, and conference proceedings were also excluded. The decision to only include papers which use a statistical method to develop the final risk model was made to differentiate between those studies which had set out to develop a risk model, using either a step-wise method or maximisation of sensitivity and specificity to select the variables for the final model, from the large number of variable-finding studies which provide tables with odds ratios or risk ratios adjusted simultaneously for all considered variables but do not attempt to generate or test a risk model. One reviewer (JUS) performed the search and screened the titles and abstracts to exclude papers that were clearly not relevant. A second reviewer (FW) independently assessed a random selection of 5% of the papers excluded at that stage. For papers where a definite decision to reject could not be made based on title and abstract alone, the full-text was examined. At least two reviewers (JUS and FW/JE/AK) independently assessed all fulltext papers, and those deemed not to meet inclusion criteria by both researchers were excluded. Papers for which it was unclear whether or not the inclusion criteria were met were discussed at consensus meetings including all researchers. Papers written in languages other than English were translated into English for assessment and subsequent data extraction.
Data extraction and synthesis
Data were extracted independently by at least two researchers (JUS and FW/JE/AK) using a standardised form to minimise bias. The form included details on: (i) the development of the model, including the study design, selection of participants, the variables considered for inclusion in the model and how they were selected; (ii) the risk model itself, including the variables included, the method of administration and whether it requires physician input or population training; (iii) the performance of the risk model in the development population, including measures of discrimination, accuracy, calibration and utility; and (iv) validation studies of the risk model and data collection tool, including the study design and performance of the risk model.
For studies which reported the step-wise performance of models, only the model with the best performance was included. For studies which included multiple different models, for example separate models for men and women or for self-assessment and physician assessment, all were included separately. One paper (16) reported models for two different age groups in additional to the cohort as a whole. In this case only the model for the entire cohort was included.
During the data extraction, risk factors were grouped into the following categories: personal characteristics; genetic factors; female hormonal factors; access to specialist skin care; personal medical history; family history; hair colour; eye colour; skin type (Fitzpatrick); skin colour, skin response to sun; history of sunburn; use of sun protection; number of naevi; number of atypical or dysplastic naevi; freckles; congenital naevi; other skin findings; new or changing naevi; sun/UV exposure (including sun bed use); and UV skin damage. Separate categories were included for skin colour, skin response to the sun, and skin type (Fitzpatrick) , which includes both skin colour and skin response to the sun (17) . If papers used the term 'skin type' but then defined that by the skin response to the sun this was extracted under skin response to the sun.
Information concerning whether the risk models required physician input or could be performed without involvement of a healthcare professional was also extracted. Risk models were classified as requiring physician input if they included any of the following factors: dysplastic or atypical naevi; actinic lentigines; total body naevus count; genetic analysis requiring samples; or specialised equipment such as dermoscopy or colorimetry. Naevus density, as in Marrett et al 1992 (18) , was not considered to require physician input as participants were provided with images representing a range of naevus density and counting of individual naevi was not required.
Reported measures of discrimination, accuracy, calibration and utility were used to compare the performance of risk models. The sensitivity and specificity of different models was also compared graphically by plotting a summary ROC curve using the MosesLittenberg method (19, 20) Meta-DiSc version 1.4 using Moses' constant for linear models to fit the summary ROC curve.
RESULTS
After duplicates were removed, the search identified 4141 papers. 4080 of these were excluded at title and abstract level. A further 42 were excluded after full-text assessment by at least two authors (JUS and FW/JE/AK). There was complete agreement amongst researchers throughout the screening process and the most common reasons for exclusion were that the papers did not use a statistical method to develop the final risk model, were conference abstracts or not primary research. Two well cited models, excluded because they were not developed using a statistical method, are those by Mar (21) and Glanz (22) . Six further papers were identified through citation searching giving 25 papers for inclusion. Of these, four provided validation of other models and four included more than one risk model. This review, therefore, describes 25 risk prediction models (Figure 1) . A summary of these 25 models, along with measures of performance in the development population and notable strengths and weaknesses, are given in Table 1 (27) and in the only model developed in a cohort study to provide a measure of performance (0.62) (28). The highest discrimination was for a model including a suspicious melanoncytic lesion on dermoscopy (0.86) (29) with a second model developed from a small case control study in Brazil where there were more cases than controls also reporting high discrimination (0.85) (30).
A measure of accuracy was provided in ten studies. The sensitivity and specificity varied between them but a summary ROC curve ( Figure 2 ) shows that they all lie very close to the curve. This shows that despite all the heterogeneity in model development and risk factors, there is very little heterogeneity in the predictive ability of the models with the variation in sensitivity and specificity likely a reflection of the cut offs chosen in different studies. The AUROC of this summary curve is 0.755.
Only three models had reported measures of calibration (28, 29, 31). All three showed good calibration but all had been tested in the development population where calibration would be expected to be high.
Further details of the development of each model are given in Supplementary Tables S1 and S2 for case-control and cohort studies respectively. Twenty-one were case-control studies and 4 cohort studies. Overall the reporting of the studies was variable. Of the 21 case-control studies, the method of selecting the variables for consideration was given in only 11, of which for 8 the method was a literature review, and the predictor variables and outcomes were evaluated in a blinded fashion in only 4. Cases were selected from either cancer registries or dermatology clinics and all required histological confirmation of diagnosis. Controls were selected from hospital clinics in 7 studies, the general population in history of skin cancer and eye colour were included in the final model in less than one in five times they were considered.
DISCUSSION
Principal findings
This is the first systematic review of risk prediction models for melanoma. It shows that multiple risk models exist and that they have the potential to identify individuals at higher risk of melanoma. Comparisons between the different models are difficult due to the lack of validation studies and heterogeneity in choice and definition of variables. Despite this, however, we show that most include well established risk factors and the AUROC of a summary ROC curve is comparable with those for other cancers, such as breast cancer (0.716-0.762) (36) and colon cancer (0.61-0.74) (37). There was also little difference in model performance between those scores suitable for self-assessment and those requiring a health care professional, suggesting potential for use at a population level to identify people at higher risk of melanoma.
Strengths and limitations
The main strengths of this review are the use of broad inclusion criteria and the systematic search of multiple databases not limited by language. This approach enabled us to identify published risk models even when developing the risk model had not been the primary aim of the study, and in doing so reduces the risk of selection bias. Whilst we cannot exclude publication bias we also expect this to be minimal because of the exploratory nature of many of the studies and the absence of performance data.
As with most systematic reviews, the main limitation is the quality of the published data. Notably, in this review it was difficult to perform direct comparisons of the risk models due to the lack of validation studies for most of the risk models. The majority of studies also gave no indication of how the authors decided which risk factors to consider for inclusion in the model and 144 different risk factors were considered with varying definitions.
Additionally, many of the risk factors are subjective in nature and subject to recall bias, which is likely to overestimate the performance of those models developed from case control studies, and only 4 included blinding of the investigator to melanoma status. By presenting all the risk models together for the first time, however, we are able to demonstrate this heterogeneity whilst making comparisons where possible.
Evaluation of the risk models
The 25 risk models differ in the risk factors included, the method of administration and their performance. Most contain established risk factors for melanoma, however, there was considerable variation amongst the definitions and measures used. In some cases, notably history of sunburn and sun / UV exposure, this likely reflects the difficulty measuring exposure to the risk factor, both due to its subjective nature and the need to recall events in the past. This is in contrast to more objective and consistent measures, such as eye colour, skin type or hair colour for which many fewer variations were seen. In other cases, particularly number of naevi and atypical and dysplastic naevi, the range of definitions probably reflects on-going uncertainty within the literature and the controversy around a nonhistological diagnosis of an atypical or dysplastic naevus (38). In all cases, however, it demonstrates the large number of variables in use within the field. Whilst it is unlikely that a single measure of each risk factor will be appropriate for all situations, increased consistency would allow more meaningful comparisons in future research.
With such a large number of risk factors considered it is perhaps not surprising that the models differ widely in the risk factors included. Most include a measure of number of 
naevi and skin type or colour and either include or adjust for age and gender but beyond that it is difficult to make generalisations.
Performance measures were only available for 16 models in the development population and two in external populations. Despite the variations already described, however, the accuracy, measured by the sensitivity and specificity, is consistent across them.
By virtue of the cut-offs set by the authors, some have higher specificity and lower sensitivity (18, 34, 35 , 39) whilst others have higher sensitivity and lower specificity (26, 31, 33). The summary ROC curve, however, shows that, despite including a range of different variables, there is very little heterogeneity in the predictive ability of the models with the variations in sensitivity and specificity reflecting different cut-offs. One reason for this may be that there is a group of core risk factors responsible for most of the increased risk. Due to the range of factors included in the different models, however, it is not possible to identify those from the available studies.
The discrimination of the models, as measured by the area under receiver operating curve, compares favourably with risk models used for other cancers, including breast cancer with AUROCs of 0.716-0.762 (36) and colon cancer with AUROCs of 0.61-0.74 (37). Care must be taken when making such comparisons, however, as many of these have been developed and validated in large cohort studies whilst the majority of melanoma risk models have been developed from case-control studies with up to 60% prevalence of melanoma which will inflate their performance through spectrum bias.
Evaluation of individual risk factors
Whilst evaluation of individual melanoma risk factors was not the primary aim of this study, by including only studies that used a statistical method to develop a risk model and extracting the number of times a risk factor was included in the final model when it was 
considered, the results of our analysis confirm the importance of several established risk factors for melanoma (23) (24) (25) . These include age, number of naevi, skin type and colour, personal history of melanoma or non-melanocytic skin cancer, freckles, dysplastic naevi and hair colour. Sun exposure, history of sunburn and skin response to the sun were also included in many of the final models but only half the times they were considered (53, 50 and 47% respectively), perhaps reflecting their subjective nature and risk of recall bias. Eye colour was also only included in 4 of the 13 models in which it was considered and this is likely to be due to known correlation between hair colour, eye colour, freckles and skin colour (23).
An unexpected finding was the absence of family history in many of the models. It was considered in 18 of the models but only remained in the final score in 6. This differs from earlier studies in which approximately 10% of cases of melanoma have reported heredity (23, 40) . It may be that other phenotypic markers which remain in the risk model are strongly correlated with family history or may simply reflect the very low incidence of true familial melanoma in the melanoma population. Some other risk factors, including for example genetic factors, ethnicity and female hormone factors, were also not considered by very many of the models and so their potential importance may be underestimated.
Implications for clinicians and policy makers
This review shows that multiple risk models for prediction of the development of melanoma exist and that they have the potential to identify individuals at higher risk of melanoma. Clinicians will be interested to see the range and relative performance of different risk models. However, all the risk scores were developed to predict risk of future disease rather than undiagnosed prevalent disease. Consequently, the results of this review will be of particular relevance to policy makers interested in the potential for using risk scores among asymptomatic people to identify a subset of the population for whom targeted screening, surveillance or educational programmes could be offered to reduce the morbidity and mortality from melanoma.
As English and Armstrong (35) point out, if a screening programme is to be directed towards a high risk group and is to have an impact on the disease as a whole, three criteria must be satisfied in addition to those for all screening programmes (41): People at high risk of the disease must be readily identifiable; those identified as being at high risk must form a large proportion of all patients who develop the disease; and this proportion must be substantially larger than the proportion of the whole population that constitutes the group at high risk. When assessed against these three criteria this review confirms that risk models exist which could be used to identify a group at higher risk of melanoma. Firstly, a number of risk models exist for which patient self-assessment is feasible and so they could be undertaken in clinical waiting rooms or via on-line platforms (16, 18, 28, 30-32, 34, 35, 39).
Secondly, those models that provide values for sensitivity and specificity suggest that screening could identify a high risk group containing between 25-89% of people expected to develop melanoma and, thirdly, that this high risk group would comprise between 10-55% of the population. These ranges are wide due to the variation in cut-offs selected in each study and reflects the trade-off between sensitivity and specificity. For example, from the summary ROC, choosing a risk score with a specificity of 50% when 50% of the population would be classified as higher risk, sensitivity is around 80% so 80% of melanomas would be detected in that higher risk group. Choosing instead a score with a specificity of 80% when 20% would identified as high risk, the sensitivity falls to around 50% so only 50% of cases would be detected. Some, including Fortes (33), believe that as melanoma can be a fatal disease but referral to a dermatologist and excision or biopsy is relatively benign, it is better to give priority to sensitivity over specificity as the inclusion of false-positive cases may be less detrimental than false-negatives. However, the utility of a risk score that identifies 50% of the population as higher risk is limited and any screening of asymptomatic people has considerable implications in terms of health care costs and both physical and psychological consequences. Several previous studies have estimated the cost-effectiveness of various melanoma screening strategies. One-off screening of a white population of all ages at average risk by a dermatologist has been shown to cost $172,276 per year-of-life-saved (YLS) (42) but this cost falls dramatically when screening is targeted to higher risk populations, defined variously by age, family history or phenotypic characteristics (10, 11, 43). Whilst a full economic analysis is beyond the scope of this review, the risk scores described are able to identify higher risk groups with greater discriminatory ability and accuracy than age, family history or phenotypic characteristics alone, and so any screening programme based on one of the risk models is likely to be even more cost-effective.
Implications for future research
The finding that many of the models have similar performance characteristics despite the wide range of different variables included suggests that developing further models based on current known risk factors is unlikely to benefit the field. As advances are made into genes that play a role in the susceptibility of melanoma (44, 45), development of new risk models incorporating genetic information may improve the discriminatory ability. Until then, further research should focus on validating existing models in different populations and assessing the costs, feasibility, acceptability and adverse consequences of applying these models. (a) Uses US Surveillance, Epidemiology and End Results Programme (SEER) and hypothetical cohort rather than testing on this case-control study population (b) From validation study in different population to development of the model (c) According to the SAMScore, a patient is considered at risk of melanoma if at least one of these 3 criteria is verified: First criterion: Presence of at least 3 risk factors among the 7 following risk factors: phototype I or II, freckling tendency, number of melanocytic naevi >20 on both arms, severe sunburn during childhood or teenage years, life in a country at low latitude, a history of previous melanoma, a history of melanoma in a first-degree relative Second criterion: A subject under 60 years of age and a number of melanocytic naevi >20 on both arms Third criterion: A subject of 60 years old or over and a freckling tendency 
